Moreover, in EGFR mutant-resistant NSCLC cells, apigenin coupled with the EGFR tyrosine kinase inhibitor gefitinib inhibited important oncogenic factors such as c-Myc, hypoxia-inducible factor 1 alpha (HIF-1α) and EGFR, and also reduced the use of glucose by suppressing the expression of its transporter, suggesting the possible use of the combination of the two molecules in clinical practice [118]. Here, EGFR is linked to non-small cell lung carcinoma.